Accessibility Menu
Biophytis logo

Biophytis(NASDAQ) BPTS

Current PriceN/A
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-86%
1 Month+0%
Biophytis last closing stock price
MetricPriceDate
Last closeUSD 0.252026-07-24
Biophytis stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.252026-06-09
1 month+0%USD 0.252026-06-09
3 month+0%USD 0.252026-04-22
Year to date+2,172.73%USD 0.012025-12-31
1 year-86.15%USD 1.812025-07-17
3 year-99.67%USD 75.202023-07-25
5 year-99.99%USD 3,360.002021-07-20
Since inception-100%USD 6,600.002021-02-10

Biophytis Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€0.00

Net Income (TTM)

-€34.66M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Sep 25, 2024

BPTS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biophytis

Biophytis S.A. is a clinical-stage biotechnology firm focused on developing therapeutic solutions to slow degenerative processes and improve functional outcomes for individuals with age-related diseases. The company targets critical biological resilience pathways to counteract the effects of various stressors contributing to age-associated pathologies.

Products and Services
  • Flagship candidate Sarconeos (BIO101) for neuromuscular conditions
  • Macuneos (BIO201) aimed at treating ophthalmic disorders
  • Collaborative efforts with AFM-Telethon for DMD treatment
Growth Outlook
  • Ongoing Phase 2/3 study for Sarconeos in COVID-19 patients
  • Potential market expansion with Macuneos for AMD and Stargardt disease
  • Strategic partnerships enhancing research and development capabilities
Financial Highlights
  • Recent quarterly net income of -€5.81 million, reflecting ongoing R&D investments
  • Cash and cash equivalents of €2.19 million as of June 30, 2024
  • Trailing twelve months (TTM) revenue of €0, indicating a focus on development
Biophytis S.A. operates in a dynamic sector with significant potential for growth, particularly in the treatment of age-related diseases. The company's commitment to research and development is evident in its substantial investments, which are crucial for advancing its innovative therapies. The ongoing clinical trials and strategic partnerships position Biophytis favorably within the biotechnology landscape, offering opportunities for future revenue generation as products progress through development stages. The financial data indicates a focus on long-term growth, with current expenditures aimed at establishing a strong market presence.
AI Generated • Jul 22, 2026

Industry

Biotechnology

Employees

20

CEO

Stanislas Veillet, PhD

Headquarters

Paris, 75005, FR

BPTS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

153.48%

Return on Capital

-324.79%

Return on Assets

-150.38%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-€2.27M

Operating Income

-€30.07M

EBITDA

-€29.34M

Operating Cash Flow

-€27.55K

Capital Expenditure

-€348.00

Free Cash Flow

-€27.90K

Cash & ST Invst.

€2.19M

Total Debt

€9.71M

Biophytis Performance Analysis

Biophytis annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 0N/A
20232023-12-31EUR 0N/A
20242024-12-31EUR 0N/A
20252025-12-31EUR 0N/A
Biophytis sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31N/A
Q22023-06-30N/A
Q42023-12-31N/A
Q22024-06-30N/A
Biophytis annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -582.24-53.3%
20232023-12-31EUR -135.57-76.7%
20242024-12-31EUR -21.73-84.0%
20252025-12-31EUR -2.33-89.3%
Biophytis sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31-39.6%
Q22023-06-3059.5%
Q42023-12-3148.5%
Q22024-06-3066.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

€0.00

N/A

Gross Profit

€0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

22

N/A

Net Income

-€5.81M

+6.2%

EBITDA

-€4.27M

+27.5%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

€2.19M

-89.1%

Total Debt

€9.71M

-32.6%

Accounts Receivable

€0.00

-100.0%

Inventory

€0.00

-100.0%

Long Term Debt

€818.00K

-81.0%

Short Term Debt

€8.89M

-12.0%

Return on Assets

-1.50%

N/A

Return on Invested Capital

97.63%

N/A

Free Cash Flow

-€5.96K

-15.9%

Operating Cash Flow

-€5.95K

-16.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PTNPalatin Technologies, Inc.
$7.71-4.10%
NOVNNovan, Inc.
$0.09-24.84%
ARAVAravive, Inc.
$0.04-13.39%
QTTBQ32 Bio Inc.
$15.15-1.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About BPTS

What is the current price of Biophytis?

Biophytis is trading at N/A per share.

What is the 52-week range for Biophytis?

Over the past 52 weeks, Biophytis has traded between N/A and N/A.

How much debt does Biophytis have?

As of the most recent reporting period, Biophytis reported total debt of €10.19M.

How much cash does Biophytis have on hand?

Biophytis reported €80.77K in cash and cash equivalents in its most recent financial results.

What is Biophytis’s dividend yield?

Biophytis does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.